Trevi Therapeutics, Inc. financial data

Symbol
TRVI on Nasdaq
Industry
Pharmaceutical Preparations
Location
195 Church Street, 14 Th Floor, New Haven, CT
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.43K % +42.3%
Debt-to-equity 8.69 % -33.8%
Return On Equity -49.9 % -89.2%
Return On Assets -45.9 % -97%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 72.6M shares +13.7%
Common Stock, Shares, Outstanding 72.6M shares +15%
Entity Public Float 106M USD +62%
Common Stock, Value, Issued 73K USD +15.9%
Weighted Average Number of Shares Outstanding, Basic 101M shares +2.37%
Weighted Average Number of Shares Outstanding, Diluted 101M shares +2.37%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 31.7M USD +51.3%
General and Administrative Expense 11.5M USD +14.2%
Operating Income (Loss) -43.2M USD -39.2%
Nonoperating Income (Expense) 4.39M USD +21%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -38.8M USD -41.6%
Income Tax Expense (Benefit) -11K USD +82.8%
Net Income (Loss) Attributable to Parent -38.8M USD -41.9%
Earnings Per Share, Basic -0.39 USD/shares -95%
Earnings Per Share, Diluted -0.39 USD/shares -95%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13M USD -5.74%
Marketable Securities, Current 56.5M USD -29.7%
Other Assets, Current 830K USD -60.1%
Assets, Current 72.1M USD -27.3%
Property, Plant and Equipment, Net 198K USD -12%
Operating Lease, Right-of-Use Asset 1.03M USD -17.1%
Other Assets, Noncurrent 273K USD +301%
Assets 73.8M USD -26.9%
Accounts Payable, Current 1.51M USD +11.8%
Accrued Liabilities, Current 4.93M USD +60%
Liabilities, Current 6.75M USD +43.3%
Operating Lease, Liability, Noncurrent 884K USD -19.6%
Other Liabilities, Noncurrent 3K USD
Liabilities 7.64M USD +29.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -84K USD +66.1%
Retained Earnings (Accumulated Deficit) -262M USD -17.3%
Stockholders' Equity Attributable to Parent 66.2M USD -30.4%
Liabilities and Equity 73.8M USD -26.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.5M USD -27.7%
Net Cash Provided by (Used in) Financing Activities -28K USD +98.4%
Net Cash Provided by (Used in) Investing Activities -8.09M USD -190%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 72.6M shares +15%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.6M USD -1881%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13M USD -5.74%
Deferred Tax Assets, Valuation Allowance 69.5M USD +13.8%
Deferred Tax Assets, Gross 70.1M USD +14.3%
Operating Lease, Liability 1.1M USD -12.5%
Depreciation 11K USD -15.4%
Payments to Acquire Property, Plant, and Equipment 57K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -38.6M USD -40.8%
Lessee, Operating Lease, Liability, to be Paid 1.35M USD -17.5%
Property, Plant and Equipment, Gross 350K USD -11.4%
Operating Lease, Liability, Current 216K USD +37.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 368K USD +5.44%
Lessee, Operating Lease, Liability, to be Paid, Year One 349K USD +15.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 245K USD -34.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 377K USD +2.45%
Deferred Tax Assets, Operating Loss Carryforwards 50.3M USD +4.74%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 95K USD -74.8%
Operating Lease, Payments 276K USD +68.3%
Additional Paid in Capital 329M USD +3.04%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 35K USD +84.2%
Interest Expense 9K USD -99.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%